Subscribe to RSS
DOI: 10.1055/s-0038-1646788
Complement-Dependent and Complement-Independent Interactions of Bacterial Lipopolysaccharides and Mucopeptides with Rabbit and Human Platelets
Publication History
Received 10 January 1978
Accepted 15 March 1978
Publication Date:
09 July 2018 (online)
Summary
The effect of 10 commercial lipopolysaccharides (LPS) and of 5 highly purified LPS with variable but defined polysaccharide content, two LPS from anaerobic bacteria, two mucopeptides and two meningococcal polysaccharides, was studied on rabbit and human platelets. All the LPS preparations induced aggregation in rabbit heparinized platelet-rich plasma (PRP) but to differing degrees. However, a preparation consisting essentially of lipid A (from Salmonella minnesota Re 595) was one of the most active. The mucopeptides were very potent whereas the meningococcal polysaccharides had no effect. The activity was abolished by inactivation of complement. The lack of ability of LPS and mucopeptides to aggregate rabbit platelets in ethyleneglycol tetraacetic acid (EGTA) – PRP suggests that the mechanism depends on activation of the classical pathway of complement. None of the bacterial products induced aggregation of human platelets.
When washed rabbit platelets are mixed with complement-depleted rabbit serum and calcium chloride, generation of thrombin occurs. Washed platelets contribute to thrombin generation by providing factor V, a factor X activating activity, and possibly phospholipid (Brit. J. Haemat. 36: 107, 1977). All the LPS preparations but not the mucopeptides or meningococcal polysaccharides enhanced the rate of thrombin formation by enhancing the factor X activating activity of rabbit or human platelets.
It is concluded that LPS affect rabbit platelets both by complement-dependent and complement-independent mechanisms, but human platelets only by the complement- independent pathway. Mucopeptides react with platelets only by the complement-dependent way and have no effect on human platelets.
-
References
- 1 Bjornson HS, Hill EO. 1973; Bacteroidaceae in thromboembolic disease: effect of cell wall components on blood coagulation in vivo and in vitro. Infection and Immunity 8: 911
- 2 Bokisch VA. 1975; Interaction of peptidoglycans with Anti-IgGs and with complement. Zeitschrift für Immunitätsforschung 149: 320
- 3 Brown DL, Lachmann PJ. 1973; The behaviour of complement and platelets in lethal endotoxin shock in rabbits. International Archives of Allergy 45: 193
- 4 Cohen P, Braunwald J, Gardner FH. 1965; Destruction of canine and rabbit platelets following intravenous administration of carbon particles or endotoxin. Journal of Laboratory and Clinical Medicine 66: 263
- 5 Davis RB, Mecker WR, Mcquarrie DG. 1960; Immediate effects of intravenous endotoxin on serotonin concentrations and blood platelets. Circulation Research 8: 234
- 6 De Gaetano G, Vermylen J, Verstraete M. 1970; Platelet aggregation by a specific human immunoglobulin preparation. Thrombosis et Diathesis Haemorrhagica 24: 419
- 7 Des Prez RM, Horowitz HI, Hook EW. 1961; Effect of bacterial endotoxin on rabbit platelets. I. Platelet aggregation and release of platelet factors in vitro Journal of Experimental Medicine 114: 857
- 8 Des Prez RM. 1967; The effects of bacterial endotoxin on rabbit platelets. V. Heat labile plasma factor requirements of endotoxin-induced platelet injury Journal of Immunology 99: 966
- 9 Fine DP, Marney Jr SR, Colley DG, Sergent JS, Des Prez RM. 1972; C 3 shunt activation in human serum chelated with EGTA. Journal of Immunology 109: 807
- 10 Fine DP. 1974; Activation of the classic and alternate complement pathways by endotoxin. Journal of Immunology 112: 763
- 11 Fong JS C, White JG, Good RA. 1974; Inhibition of endotoxic lipopolysaccharide- mediated platelet aggregation by cobra venom anticomplementary factor. Blood 44: 399
- 12 Galanos C, Rietschel ET, Luderitz O. et al. 1971; Interaction of lipopolysaccharides and lipid A with complement. European Journal of Biochemistry 19: 143
- 13 Galanos C. 1975; Physical state and biological activity of lipopolysaccharides. Toxicity and immunogenicity of the lipid A component Zeitschrift für Immunitätsforschung 149: 214
- 14 Gotschlich EC, Liu TY, Artenstein MS. 1969; Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides Journal of Experimental Medicine 129: 1349
- 15 Gotze O, Muller-Eberhard HJ. 1971; The C3-activator system: an alternate pathway of complement activation. Journal of Experimental Medicine 134: 90 s
- 16 Hofstad T, Kristoffersen T. 1970; Chemical characteristics of endotoxin from Bacteroides fragilis NCTC 9343. Journal of General Microbiology 61: 15
- 17 Horowitz HI, Des Prez RM, Hook EW. 1962; Effects of bacterial endotoxin on rabbit platelets. II. Enhancement of platelet factor 3 activity in vitro and in vivo Journal of Experimental Medicine 116: 619
- 18 Johnsson H, Niklasson PM. 1976; Effects of meningococcal and Escherichia coli capsular polysaccharides on human and dog platelet aggregation in vitro. Journal of Clinical Pathology 29: 438
- 19 Kane MA, May JE, Frank MM. 1973; Interaction of the classical and alternate complement pathway with endotoxin lipopolysaccharide. Effect on platelets and blood coagulation Journal of Clinical Investigation 52: 370
- 20 Loos N, Bitter-Suermann D, Dierich M. 1974; Interaction of the first (C 1), the second (C 2) and the fourth (C 4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. Journal of Immunology 112: 935
- 21 Luderitz O, Westphal O, Staub AM. et al. 1971. Isolation and chemical and immunological characterization of bacterial LPS. In: Weinbaum G, Kadis S, Ajl SJ. (eds.) Microbial Toxins. Academic Press; New York: vol. 4 p 145
- 22 Luderitz O, Galanos C, Lehmann V. et al. 1973; Lipid A: chemical structure and biological activity. Journal of Infectious Diseases 128: 17
- 23 Marcus RL, Shin HS, Mayer MM. 1971; An alternative complement pathway: C 3-cleaving activity not due to C 4, 2a on endotoxin lipopolysaccharide after treatment with guinea pig serum; relation to properdin. Proceedings of the National Academy of Sciences 88: 1351
- 24 Marney jr SR, Colley DG, Des Prez RM. 1975; Alternate complement pathway induction of aggregation and release of 5-hydroxytryptamine and adenosine diphosphate by rabbit platelets. Journal of Immunology 114: 696
- 25 Mckay DG, Margaretten W, Csavossy I. 1966; An electron microscope study of the effect of bacterial endotoxin on the blood vascular system. Laboratory Investigation 15: 1815
- 26 Morrison DC, Leive L. 1975; Fractions of lipopolysaccharide from Escherichia coli 0111:B4prepared by two extraction procedures. Journal of Biological Chemistry 250: 2911
- 27 Morrison DC, Kline LF. 1977; Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). Journal of Immunology 118: 362
- 28 Nagayama M, Zucker MB, Beller FK. 1971; Effects of a variety of endotoxins on human and rabbit platelet function. Thrombosis et Diathesis Haemorrhagica 26: 467
- 29 Pfueller SL, Luescher EF. 1974; Studies of the mechanism of the human platelet release reaction induced by immunologic stimuli. I. Complement-dependent and complement-independent reactions Journal of Immunology 112: 1201
- 30 Raskova H, Ryc M, Rotta J. 1971; Release of 5-hydroxytryptamine and morphological changes in blood platelets induced by mucopeptide of streptococcal cell walls. Journal of Infectious Diseases 123: 587
- 31 Rotta J, Schleifer KH. 1974; Pyrogenic activity of bacterial mucopeptides. Journal of Hygiene, Epidemiology, Microbiology and Immunology (Praha) 18: 50
- 32 Rotta J. 1975; Endotoxin-like properties of peptidoglycan. Zeitschrift für Immunitätsforschung 149: 230
- 33 Ryc M, Rotta J. 1975; The thrombocytolytic activity of bacterial peptidoglycans. Zeitschrift für Immunitätsforschung 149: 230
- 34 Semeraro N, Vermylen J. 1977; Evidence that washed human platelets possess factor-X activator activity. British Journal of Haematology 36: 107
- 35 Semeraro N, Fumarola D, Mertens F, Vermylen J. 1978; Evidence that endotoxins enhance the factor-X activator activity of washed human platelets. British Journal of Haematology 38: 243
- 36 Siraganian RP. 1972; Platelet requirement in the interaction of the complement and clotting system. Nature New Biology 239: 208
- 37 Snyderman R, Pike MC. 1975; Interaction of complex polysaccharide with the complement system: effect of calcium depletion on terminal complement consumption. Infection and Immunity 11: 273
- 38 Spielvogel AR. 1967; An ultrastructural study of the mechanism of platelet-endotoxin interaction. Journal of Experimental Medicine 126: 235
- 39 Tangen O, Berman HJ. 1972; Gel filtration of blood platelets: a methodological report. Advances in Experimental Medicine and Biology 34: 235
- 40 Vargues R. 1967; Le dosage du complément. Transfusion (Paris) 3: 277
- 41 Walsh PN, Biggs R, Gagnatelli G. 1974; Platelet anti-heparin activity. Assay based on factor-Xa inactivation by heparin and antifactor Xa British Journal of Haematology 26: 405
- 42 Zimmerman TS, Mueller-Eberhard HJ. 1972; Interaction of complement, platelets and the blood coagulation system. Journal of Clinical Investigation 51: 107a
- 43 Zimmerman TS. 1973; The platelet in complement coagulation interaction. Advances in Biosciences 12: 291
- 44 Zucker MB, Grant RA. 1974; Aggregation and release reaction induced in human blood platelets by zymosan. Journal of Immunology 112: 1219